(Q35167447)

6 August 2017

1 reference

title

Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials (English)

1 reference

6 August 2017

Barbara B M Kortmann

1

1 reference

6 August 2017

Diamandis L Floratos

2

1 reference

6 August 2017

Lambertus A L M Kiemeney

3

1 reference

6 August 2017

Hessel Wijkstra

4

1 reference

6 August 2017

Jean J M C H de la Rosette

5

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

6 August 2017

1 reference

6 August 2017

62

1 reference

6 August 2017

1

1 reference

6 August 2017

1-9

1 reference

New words for old: lower urinary tract symptoms for "prostatism"

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Bladder outlet obstruction versus impaired detrusor contractility: the role of outflow

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Lack of correlation of the American Urological Association Symptom 7 Index with urodynamic bladder outlet obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

The Correlation Between Bladder Outlet Obstruction and Lower Urinary Tract Symptoms as Measured by the International Prostate Symptom Score

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Is obstruction predictable by clinical evaluation in patients with lower urinary tract symptoms?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Relationships between lower urinary tract symptoms and bladder outlet obstruction: Results from the ICS-“BPH” Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Urodynamic Assessment and Quantification of Prostatic Obstruction before and after Transurethral Resection of the Prostate: Standardization with the Aid of the Computer Program CLIM

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Overview of alpha-blocker therapy for benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Long-term implications of medical therapy on benign prostatic hyperplasia end points

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Adrenergic and Cholinergic Receptors in the Human Prostate, Prostatic Capsule and Bladder Neck

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Localization of the alpha 1A-adrenoceptor in the human prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

The concept of uroselectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Functional uroselectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Effects of Prazosin in Patients with Benign Prostatic Obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Effects of prazosin and carbachol in patients with benign prostatic obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

A twelve-week placebo-controlled study of prazosin in the treatment of prostatic obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Prazosin in the Treatment of Prostatic Obstruction A Placebo-controlled Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Effect of terazosin on urine storage and voiding in the aging male with prostatism

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Urodynamic and Clinical Effects of Terazosin Therapy in Patients with Symptomatic Benign Prostatic Hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

Standardization of terminology of lower urinary tract function: pressure-flow studies of voiding, urethral resistance, and urethral obstruction. International Continence Society Subcommittee on Standardization of Terminology of Pressure-Flow Studies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902113-1

7 January 2021

10.1016/S0090-4295(02)02113-1

Identifiers

DOI

1 reference

6 August 2017

1 reference